文献速递心力衰竭与心肌病

静脉羧基麦芽糖铁对急性心衰合并铁缺乏患者健康相关生活质量的影响:AFFIRM-AHF 研究结果

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
PubMed 文献 · Eur Heart J · 2021-01-01

AFFIRM-AHF 研究评估静脉羧基麦芽糖铁(FCM)与安慰剂对急性心衰稳定后铁缺乏患者健康相关生活质量(HRQoL)的影响,共 1058 例患者完成基线 KCCQ-12 问卷。结果显示,从第 4 周至第 24 周,FCM 组 KCCQ-12 总体汇总评分和临床汇总评分的改善均显著优于安慰剂组;第 52 周时疗效有所减弱但仍有利于 FCM。

要点

  • 静脉 FCM 可改善急性心衰稳定后铁缺乏患者的 HRQoL,第 4 周即出现差异。
  • 第 4 周 OSS 调整后平均差异 2.9(95%CI 0.5-5.3,P=0.018),CSS 为 2.8(0.3-5.3,P=0.029)。
  • 第 24 周 OSS 差异 3.0(0.3-5.6,P=0.028),CSS 差异 2.9(0.2-5.6,P=0.035)。

核心结论

  • 在急性心衰稳定后且左室射血分数<50% 的铁缺乏患者中,静脉 FCM 较安慰剂在治疗开始后 4 周即对 HRQoL 产生有临床意义的获益,并持续至第 24 周。

研究设计与样本

  • AFFIRM-AHF 研究的事后分析,比较静脉 FCM 与安慰剂对 HRQoL 的影响。
  • 共 1058 例患者完成基线 KCCQ-12 问卷,其中 FCM 组 535 例,安慰剂组 523 例。
  • KCCQ-12 在随机化前及第 2、4、6、12、24、36、52 周进行评价。

主要发现

  • 基线 KCCQ-12 OSS 均值±标准误:FCM 组 38.7±0.9,安慰剂组 37.1±0.8;CSS 分别为 40.9±0.9 和 40.1±0.9。
  • 第 2 周时,FCM 组与安慰剂组的 OSS 和 CSS 变化相似。
  • 第 4 周至第 24 周,FCM 组 OSS 和 CSS 改善显著优于安慰剂组。
  • 第 4 周 OSS 调整后平均差异 2.9(95%CI 0.5-5.3,P=0.018),CSS 为 2.8(0.3-5.3,P=0.029)。
  • 第 24 周 OSS 调整后平均差异 3.0(95%CI 0.3-5.6,P=0.028),CSS 为 2.9(0.2-5.6,P=0.035)。

临床怎么用

  • 对于急性心衰稳定后且左室射血分数<50% 的铁缺乏患者,可考虑静脉 FCM 以改善健康相关生活质量。
  • HRQoL 获益在治疗开始后 4 周即可显现,并可持续至第 24 周,可作为评估疗效的参考时间点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. METHODS AND RESULTS: The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean ± standard error was 38.7 ± 0.9 (FCM group) and 37.1 ± 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 ± 0.9 and 40.1 ± 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. CONCLUSION: In iron-deficient patients with HF and left ventricular ejection fraction <50% who had stabilized after an episode of acute HF, treatment with IV FCM, compared with placebo, results in clinically meaningful beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to Week 24.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021. PMID: 34080008. doi:10.1093/eurheartj/ehab234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。